Drug Discovery

Aptorum to investigate use of repurposed drug candidates for coronavirus

Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).

Sanofi, Translate Bio to develop novel mRNA vaccine for COVID-19 disease

Sanofi’s vaccines global business unit Sanofi Pasteur has collaborated with Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

Novartis, life sciences firms collaborate with BMGF to fight against COVID-19 disease

Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

ClinOne’s remote clinical trial patient management technology allows pharmaceutical companies to continue clinical research efforts amidst Covid-19 pandemic in accordance with FDA guidelines

The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible.

Xencor, Vir Biotechnology collaborate on Xtend XmAb antibody technology for COVID-19

Xencor and Vir Biotechnology have entered into a technology licence agreement for the use of Xtend XmAb Fc technology in investigational antibodies for the treatment of COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.

Hoth Therapeutics announces agreement to joint development for a self-assembling vaccine (SAV) for the potential prevention of coronavirus

Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate.

Design Therapeutics launches with $45m to develop a new class of disease-modifying therapies for serious degenerative disorders

Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions.

Entos to develop Fusogenix DNA vaccine to prevent COVID-19 infections

Healthcare biotechnology company Entos Pharmaceuticals has unveiled plans to develop a Fusogenix DNA vaccine for the prevention of COVID-19 infections.

RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration

RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").